SCHEMBL6324867

SCHEMBL6324867

CCOc1ccc(S(=O)(=O)N(C)CC(C)S)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.70
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MMP2 P08253 1/20 0.45
MMP7 P09237 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
POLB P06746 1/20 0.44
CNR2 P34972 1/20 0.44
TSHR P16473 2/20 0.42
HPGD P15428 1/20 0.42
LMNA P02545 3/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325753 0.89 ADAM17 (0.67) ADAM17CA12CA1CA2CA7
SCHEMBL6323360 0.86 ADAM17 (0.64) ADAM17CA12CA1CA2CA7
SCHEMBL6330964 0.85 ADAM17 (0.52) ADAM17CA12CA1CA2CA7
SCHEMBL6323224 0.85 ADAM17 (0.65) ADAM17ALDH1A1SMN1; SMN2MMP2MMP8
SCHEMBL6320959 0.81 ADAM17 (0.61) ADAM17ALDH1A1SMN1; SMN2MMP2MMP8
SCHEMBL22104936 0.80 CA12 (0.56) ADAM17CA12CA1CA2CA7
SCHEMBL28109405 0.78 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL20733374 0.77 LMNA (0.66) CA12CA1CA2CA7CA9
SCHEMBL6324864 0.77 CA12 (0.49) ADAM17CA12CA1CA2CA7
SCHEMBL6324860 0.77 CA12 (0.49) ADAM17CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 ADAM17 27/4885CA12 248/4885CA1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.